Clinical Trials Browser

INDUSTRY × Arsenic Trioxide × Clear all

NCT07296445 2025-12-29

LATITUDE

Phase 3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Promyelocytic, Acute

NCT06882031 2025-11-18

Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT04996030 2024-01-23

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

Phase 1 Suspended

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT00017433 2020-10-06

Arsenic Trioxide in Treating Patients With Multiple Myeloma

Phase 2 Terminated

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00017069 2020-10-05

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

Phase 2 Terminated

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00020969 2020-10-05

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Phase 2 Terminated

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT02066870 2015-03-13

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung